




EMLc

ATC codes: [A07AA06](#)

Indication	Visceral leishmaniasis <span>ICD11 code: <a href="#">1F54.0</a></span>
INN	Paromomycin
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Formulations	Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
EML status history	First added in 2007 ( <a href="#">TRS 946</a> ) Changed in 2007 ( <a href="#">TRS 950</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Paromomycin</a> 
DrugBank	<a href="#">Paromomycin</a> 

## Summary of evidence and Expert Committee recommendations

Paromomycin was considered at the 15th Expert Committee meeting in March 2007, where paromomycin solution for intramuscular (IM) injection was added to the Model List. The Expert Committee concluded that paromomycin was effective in terms of effect on standard endpoints, such as initial and final cure, for the treatment of visceral leishmaniasis in children and adults. Paromomycin is licensed in India, and was granted orphan drug designation by the US Food and Drug Administration (FDA) in March 2005 and the European Medicines Agency (EMA) in April 2005. The EMLc Subcommittee endorsed the listing of paromomycin IM injection on the first EMLc.

